Market News & Trends
Evonik Completes Multi-Million Dollar Expansion of its CMO Capabilities for API & Advanced Intermediates
Evonik, a global CMO leader for API and advanced intermediates, recently announced the completion of a 36-million euro expansion of its contract manufacturing capabilities in the US and Europe.
PCI Pharma Services Announces Agreement to Acquire Sherpa Clinical Packaging
PCI Pharma Services recently announced the acquisition of San Diego-based Sherpa Clinical Packaging, which expands PCI’s US operations to the West Coast. The acquisition of…
SAMDI Tech Increases Clients’ Opportunities for Drug Candidate Hit Finding With Charles River Partnership
SAMDI Tech, Inc., the industry’s leading provider of label-free drug discovery solutions, has partnered with Charles River Laboratories, which provides products and services that accelerate…
IMV Announces Phase 2 Basket Trial in Collaboration With Merck
IMV Inc. recently announced it has expanded its clinical program with a Phase 2 basket trial evaluating its lead candidate, DPX-Survivac, in combination with low-…
Telix Completes Acquisition of Atlab for Prostate Cancer Program
Telix Pharmaceuticals Limited recently announced completion of the acquisition of Atlab Pharma SAS. The option to acquire Atlab for the consideration of $10 million (in…
Dalton Pharma Services Invests in Fully Automated Sterile Liquid Filling System
As a part of a $10-million dollar facility and capital expansion, Dalton Pharma Services, a leading North American contract research, development & manufacturing organization, has…
Pfanstiehl Launches New cGMP-Produced, Parenteral-Grade Arginine for Biopharmaceutical & Pharmaceutical Formulations
As Pfanstiehl approaches its 100th anniversary in 2019, the company has launched a new high purity, low endotoxin, and low metal L-Arginine (USP, EP, JP,…
VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate
VistaGen Therapeutics, Inc. and Pherin Pharmaceuticals, Inc. recently announced the signing of a license agreement granting VistaGen exclusive worldwide rights to develop and commercialize PH94B nasal spray, a Phase 3-ready drug candidate for as-needed (PRN) treatment of Social Anxiety Disorder (SAD).
PAREXEL Advances Patient-Centric Drug Development With Introduction of its Patient Innovation Center
PAREXEL International Corporation, a leading innovator of global biopharmaceutical services, today announced the launch of its Patient Innovation Center, designed to help guide sponsors in their efforts to improve efficiency and success across all areas of biopharmaceutical development including clinical trial design, recruitment, execution and market access.
Sandoz & Teva Have Potential to Transform Epinephrine Injection Market
With no generic versions and few comparable alternatives, Mylan’s EpiPen has dominated the epinephrine injection device market for over a decade. However, this summer has…
Inoviem Scientific Enters Into Service-Based Partnership With XoNovo
Inoviem Scientific recently announced a service-based partnership with XoNovo, a preclinical-stage biopharmaceutical company developing a proprietary small molecule for the treatment of neurodegenerative diseases. Financial…
Opiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial
Opiant Pharmaceuticals, Inc. recently announced it has completed patient enrollment in its Phase 2 clinical trial of OPTN001, a naloxone nasal spray, for the treatment…
Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial
Pieris Pharmaceuticals, Inc. recently announced it has dosed the first patient in the company’s Phase 1 combination clinical trial of PRS-343, its lead proprietary immuno-oncology…
MilliporeSigma Launches Next-Generation Process Technologies for Intensified Drug Production
MilliporeSigma recently launched three new products to help biomanufacturers navigate the evolving biopharma landscape with increased speed, greater flexibility, and enhanced quality. These next-generation process…
Aucta Pharmaceuticals Signs Commercial Manufacturing Agreement With Catalent
Catalent Pharma Solutions recently announced a commercial supply agreement for Aucta Pharmaceuticals, Inc.’s (Aucta) vigabatrin. The agreement follows a successful development program to formulate vigabatrin…
Biothera Pharmaceuticals Announces Immuno-Oncology Clinical Trial Collaboration With AstraZeneca
Biothera Pharmaceuticals, Inc. recently announced a clinical collaboration with AstraZeneca to evaluate whether the combination of Biothera’s Imprime PGG and AstraZeneca’s durvalumab (IMFINZI) can decrease tumor volume in patients with primary untreated locally advanced head and neck cancer prior to surgical resection.
Metrion Biosciences & AMRI Collaborate to Offer Ion Channel Drug Discovery Services
Metrion Biosciences Limited and AMRI recently announced they have signed a new collaboration agreement. The alliance will promote Metrion’s electrophysiology and ion channel screening expertise to global pharmaceutical and biotechnology clients.
CURE Pharmaceutical Expands Distribution of CUREfilm Technology With First Licensing Agreement
CURE Pharmaceutical recently announced it entered into a multi-year licensing agreement for the first time with a leading international cannabis company.
Reata Announces Receipt of $30-Million Milestone Payment
Reata Pharmaceuticals, Inc. recently announced it has received a $30-million milestone payment from its licensee, Kyowa Hakko Kirin Co., Ltd. following the initiation of AYAME, a Phase 3 clinical trial to assess the efficacy and safety of bardoxolone methyl (bardoxolone) for the treatment of diabetic kidney disease in Japan.
Emisphere’s Proprietary Eligen Technology Supports Novo Nordisk’s Oral Semaglutide
Novo Nordisk A/S recently announced the headline results from PIONEER 5, a Phase 3a trial with oral semaglutide in adults with type 2 diabetes and…
